Revenue: As of FY2025 Q1, the actual value is USD 231.3 M.

EPS: As of FY2025 Q1, the actual value is USD -4.38.

EBIT: As of FY2025 Q1, the actual value is USD 112.35 M.

Segment Revenue

• Q1 2025 Revenues: $231.3 million, a decrease of 1.4% compared to $234.5 million in Q1 2024.

Operational Metrics

• Net Loss: $71.3 million for Q1 2025, compared to $539.7 million for Q1 2024.
• Adjusted EBITDA: $142.1 million for Q1 2025, compared to $146.8 million for Q1 2024.
• Operating Income: $9.7 million for Q1 2025, compared to an operating loss of $486.4 million for Q1 2024.

Cash Flow

• Net Cash Used by Operating Activities: - $30.1 million for Q1 2025, compared to net cash provided by operating activities of $49.7 million for Q1 2024.
• Free Cash Flow: - $68.9 million for Q1 2025, compared to $19.2 million for Q1 2024.

Unique Metrics

• The Company processed approximately $42.9 billion in claim charges during Q1 2025, identifying potential medical cost savings of approximately $6.2 billion.

Outlook / Guidance

• Claritev reaffirms its full-year 2025 guidance, expecting revenues to be between a 2% decrease to flat compared to FY 2024, with an Adjusted EBITDA Margin of 62.5% to 63.5%.
• Capital expenditures are projected to be between $155 million to $165 million, and Free Cash Flow is expected to be between - $65 million to - $75 million.